DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro.
Verheijen M, Lienhard M, Schrooders Y, Clayton O, Nudischer R, Boerno S, Timmermann B, Selevsek N, Schlapbach R, Gmuender H, Gotta S, Geraedts J, Herwig R, Kleinjans J, Caiment F. · 2019
Read DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. by Verheijen M, Lienhard M, Schrooders Y, Clayton O, Nudischer R, Boerno S, Timmermann B, Selevsek N, Schlapbach R, Gmuender H, Gotta S, Geraedts J, Herwig R, Kleinjans J, Caiment F. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6420634.txt.
Introduction
Verheijen and co-authors report a solvent study in Scientific Reports. DMSO is used widely in labs, for freezing cells and dissolving drugs. Regulators once classed it among the safest solvents, and its own effects were often ignored.
The team exposed heart and liver microtissues to 0.1 percent DMSO. Gene activity, proteins, and DNA methylation all shifted in both tissue types. More than two thousand genes changed in each tissue, early results show. Such shifts could skew lab results that use DMSO as a neutral carrier. The authors urge labs to treat DMSO as an active ingredient.
Catalog record
| CREATOR | Verheijen M, Lienhard M, Schrooders Y, Clayton O, Nudischer R, Boerno S, Timmermann B, Selevsek N, Schlapbach R, Gmuender H, Gotta S, Geraedts J, Herwig R, Kleinjans J, Caiment F. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro By M Verheijen, M Lienhard, Y Schrooders, O Clayton, R Nudischer, S Boerno, B Timmermann, N Selevsek, R Schlapbach, H Gmuender, S Gotta, J Geraedts Published in: Scientific Reports DOI: 10.1038/s41598-019-40660-0 ABSTRACT Abstract Though clinical trials for medical applications of dimethyl sulfoxide (DMSO) reported toxicity in the 1960s, later, the FDA classified DMSO in the safest solvent category. DMSO became widely used in many biomedical fields and biological effects were overlooked. Meanwhile, biomedical science has evolved towards sensitive high-throughput techniques and new research areas, including epigenomics and microRNAs. Considering its wide use, especially for cryopreservation and in vitro assays, we evaluated biological effect of DMSO using these technological innovations. We exposed 3D cardiac and hepatic microtissues to medium with or without 0.1% DMSO and analyzed the transcriptome, proteome and DNA methylation profiles. In both tissue types, transcriptome analysis detected >2000 differentially expressed genes affecting similar biological processes, thereby indicating consistent cross-organ actions of DMSO. Furthermore, microRNA analysis revealed large-scale deregulations of cardiac microRNAs and smaller, though still massive, effects in hepatic microtissues. Genome-wide methylation patterns also revealed tissue-specificity. While hepatic microtissues demonstrated non-significant changes, findings from cardiac microtissues suggested disruption of DNA methylation mechanisms leading to genome-wide changes. The extreme changes in microRNAs and alterations in the epigenetic landscape indicate that DMSO is not inert. Its use should be reconsidered, especially for cryopreservation of embryos and oocytes, since it may impact embryonic development. INTRODUCTION Dimethyl sulfoxide (DMSO) is an organic polar aprotic molecule with an amphipathic nature that is ideal for dissolving poorly soluble polar and non-polar molecules. DMSO is widely used as solvent in toxicology and pharmacology, for cryopreservation of cells, and as penetration enhancer during topological treatments. The use of DMSO is so obvious that applied concentrations are often unreported. DMSO is generally accepted as nontoxic below 10% (v/v) and, in practice, it is assumed that effects of DMSO are negligible1–3. Research from the 1960’s till 1990’s pinpointed a lot of biologically relevant effects of DMSO. It was even actively investigated for medical use, but because of adverse effects especially affecting the eyes, most clinical trials were halted in 1965 by the United States Food and Drug Administration (FDA). At this point in time, DMSO was seen as extremely toxic, comparable to thalidomide4,5. The effects of DMSO differ depending on dose and route of administration. Introducing DMSO concentrations higher than 50% into the blood resulted in instant hemolysis, white cell stacking and fibrinogen precipitation while direct injection of DMSO intravenously could cause local irritation and necrosis6. LD50 values gained from monkeys indicated that 880 grams applied on the skin or 320 grams injected intravenously would result in 50% mortality in 80 kg humans7. This relatively high dose changed the view on DMSO toxicity and the FDA classified DMSO in the same class as ethanol, namely class 3 solvent, which is the safest category with low toxic potential at levels normally accepted in pharmaceuticals8. This made the wide use of DMSO possible. While generally used at relatively low concentrations, DMSO still has medically useful properties such as inducing anti-inflammation, nerve blockage (analgesia), diuretics, vasodilation and muscle relaxation9. Furthermore, in cell biology, DMSO is also used as inducer of cell differentiation, free radical scavenger and radioprotectant, but most often for cryopreservation. Cell cultures for research are often stored in liquid nitrogen using slow cooling methodology. To prevent damage by intracellular ice crystals, cells are slowly cooled to −80 degrees in the presence of 10% DMSO before storage in liquid nitrogen3. However, this procedure is insufficient for biomedical applications. Because slow cooling still induces damage due to extracellular ice crystals, cryopreservation of human oocytes and embryos for in vitro fertilization (IVF) is accomplished by vitrification, in which higher concentrations of cryoprotectants are used to prevent ice formation not only in the cells, but in the entire solution. Higher concentrations are achieved by using mixtures (for example 15% DMSO in combination with 15% ethylene glycol) which reduces the amount and toxicity of the individual cryoprotectants10. Furthermore, DMSO readily crosses most tissue membranes of lower animals and man9. For example, 2 hours after topological application, DMSO had penetrated all investigated hard and soft tissues (6 and 15 resp.) in rats11. DMSO is also able to enhance the permeability of other low molecular weight compounds, thereby making them pass membranes or going deeper into a tissue as they normally would12, a property highly useful in topological therapies. In 2009, the first to obtain FDA approval for topological DMSO usage was PENNSAID®, which contains diclofenac in a carrier with 45.5% DMSO13,14. This relatively high concentration of DMSO in topological applications is necessary because the skin is harder to penetrate than cell membranes. Most insights into the molecular effects of DMSO were obtained last century often using high doses. In the meantime, biomedical science has evolved towards more sensitive high-throughput techniques and towards new areas of research, including epigenome modifications and microRNA-mediated gene silencing. Considering its wide use in many biological fields, we analyzed a relatively low dose of DMSO (0.1%, which is commonly applied in cell assays) to study the impact on the proteome, transcriptome and the epigenome. For this, we exposed in vitro 3D microtissues (a maturing iPSC-derived cardiac model and a mature hepatic model) to 0.1% DMSO and we collected samples in triplicate at 7 different time points during 2 weeks exposure (2 h, 8 h, 24 h, 72 h, 168 h, 240 h and 336 h). Thereafter, DMSO effects were assessed with full transcriptome analysis (using ribo-depleted total RNA sequencing and microRNA sequencing), whole-genome methylation profiling (using MeDIP-seq) and proteomics analysis (using mass spectrometry). Our analysis clearly demonstrated that DMSO cannot be considered biologically inert but induces large alterations in microRNAs (miRNA) and epigenetic landscape, especially in the maturing cardiac model. RESULTS Human 3D microtissues (MTs) of a maturing cardiac model and a mature hepatic model were exposed to culture medium with or without 0.1% DMSO for two weeks with sampling time points at 2, 8, 72, 168, 240 and 336 hours. The proteome (approximately 2,000 measured proteins), the full transcriptome (including miRNAs) and whole-genome methylation were measured on material obtained from the same sample. Figure 1 contains a graphical overview of the experimental design. In order to obtain a first overview of DMSO-induced cross-omics effects, amounts of differentially changed entities (all corrected for multiple testing using FDR <0.05) are summarized for each platform. Numbers of differentially changed entities differed between the tissue types, with cardiac samples showing a larger effect of DMSO than hepatic, with the exception of mRNAs. This difference is especially noticeable for miRNAs and genome methylation. Because proteomics data was least informative due to its partial nature, these results were included in Supplementary Data. Furthermore, principal component analysis (PCA), using averages of triplicates, for each platform (Fig. 2 & Supplementary Data) depicts clear differences between 0.1% DMSO exposed (DMSO) and untreated (UNTR) samples, with the exception of methylation in hepatic MTs. [Figure: Graphical overview of experimental design combined with summary of differential entities of each analysis method. Tissue-specific information is depicted in orange for cardiac and green for hepatic. Furthermore, exposures are coloured blue and